SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

Shares of MLTX are trending amid a steep decline following mixed results from a Phase 3 trial, leading to significant community discussion around potential short covering and whether the market has overreacted. Some investors are speculating about a possible acquisition by Merck, while others are assessing the company's cash reserves and future prospects. The conversation highlights the volatile nature of biotech stocks and the high-risk, high-reward potential in the sector.

Applied DNA Sciences, Inc. is a biotechnology company, which engages in the development and commercialization of technologies to produce and detect deoxyribonucleic acid and ribonucleic acid. It operates through the following segments: Therapeutic DNA Production Services, MDx Testing Services, and DNA Tagging and Security Products and Services. The Therapeutic DNA Production Services segment consists of the enzymatic manufacture of synthetic DNA for use in the production of nucleic acid-based therapeutics and, the development and sale of a proprietary RNAP for use in the production of mRNA therapeutics. The MDx Testing Services segment develops clinical molecular diagnostic and genetic tests and clinical laboratory testing services. The DNA Tagging and Security Products and Services segment is involved in the detection of DNA for industrial supply chains and security services. The company was founded in 1983 and is headquartered in Stony Brook, NY.

Applied Dna Sciences Inc

APDN is trending following news of a $58M private placement to initiate a BNB-focused digital asset strategy, with plans to change its ticker to BNBX; the stock experienced multiple trading halts as a result. The community is discussing the potential for a significant price increase, with some drawing comparisons to other low-float runners and noting Scaramucci's involvement as an advisor. This activity occurs amid broader speculation about the company's strategic shift towards digital assets.

Aurinia Pharmaceuticals, Inc. is a clinical stage bio-pharmaceutical company, which engages in the research, development, and commercialization of therapeutic drugs. The company was founded by Robert Foster, Richard Glickman, and Michael Martin on June 16, 1993 and is headquartered in Edmonton, Canada.

Aurinia Pharmaceuticals Inc

Aurinia Pharmaceuticals ($AUPH) is trending due to an ex-FDA employee's LinkedIn post questioning the safety and efficacy of their drug Lupkynis, sparking concerns about potential market manipulation. The community is debating the validity of the claims, the company's response, and possible legal action. Some investors believe this is a strategic move to lower the price before a buyout, while others worry about the drug's reputation and future sales.

Robinhood Markets, Inc is a financial services platform, which engages in the provision of retail brokerage and offers trading in U.S. listed stocks and Exchange Traded Funds, related options, and cryptocurrency trading, as well as cash management, which includes debit cards services. The company was founded by Vladimir Tenev and Baiju Prafulkumar Bhatt in 2013 and is headquartered in Menlo Park, CA.

Robinhood Markets Inc - Ordinary Shares - Class A

Robinhood Markets Inc

Robinhood ($HOOD) is trending as it reached new all-time highs, driven by optimism around its prediction markets business and expansion into new fintech services. Community members are actively discussing the stock's potential to continue its impressive run, while some caution against overvaluation and a possible pullback. Bullish sentiment is fueled by strong financials and the stock's inclusion in the S&P 500.

American Battery Technology Co. is a technology company, which engages in the development and marketing of lithium-ion batteries. Its projects include recycling plant, United States Advanced Battery Consortium (USABC), and Tonopah flats. The company was founded on October 6, 2011 and is headquartered in Reno, NV.

American Battery Technology Company

American Battery Technology Company is trending as investors eagerly anticipate the release of its Preliminary Feasibility Study (PFS), with some speculating its imminent arrival could trigger a significant price surge. Bullish sentiment is fueled by increasing volume, government backing, and potential short squeezes, while community members express excitement about the company's long-term prospects in the lithium and battery recycling sectors.

A project grown out of the community's love and passion for the weed culture. Launched around early 2025, $weedcoin, “Like Bitcoin but way higher,” emphasizes its alignment with cannabis culture and a laid-back vibe. Unlike other Weed communities, this project leans heavily into community engagement over technical utility, aiming to build a “stoner community” through social media presence and decentralized governance. We also aim to focus on onboarding web2 businesses and users onto web3 through the token.

Weedcoin

Weedcoin is trending as a 'culture coin' and a way to invest in the cannabis space. Community members are drawn to its focus on freedom, community, and growth, viewing it as more than just a token. Bullish sentiment is also fueled by broader discussions around potential cannabis legalization.

Boqii Holding Ltd. operates as a holding company with interest in operating online pet stores. It provides services through its subsidiaries. The company was founded by Liang Hao, Tang Yingzhi, and Chen Di in December 2007 and is headquartered in Shanghai, China.

Boqii Holding Limited - Ordinary Shares - Class A

Boqii Holding Limited - ADR

Boqii Holding Limited is trending amid high volatility, with community members debating whether it's primed for another surge or a pullback. Discussions revolve around its low float and potential for a short squeeze, while some caution against the risks associated with Chinese stocks. The stock's recent price action and potential technical patterns are also being closely watched by traders.

Solana is a highly functional open source project that banks on blockchain technology’s permissionless nature to provide decentralized finance (DeFi) solutions. It is a layer 1 network that offers fast speeds and affordable costs. While the idea and initial work on the project began in 2017, Solana was officially launched in March 2020 by the Solana Foundation with headquarters in Geneva, Switzerland.

Solana

Solana is trending as the community discusses its potential to reclaim higher price levels, with some anticipating ETF approvals could act as a catalyst. Chatter includes discussion of meme coins built on the Solana blockchain and the overall bullish sentiment for "Uptober". Technical analysis suggests $SOL.X is showing signs of strength after bouncing off a key Fibonacci retracement level.

Cava Group, Inc. is a holding company, which engages in the category-defining Mediterranean fast-casual restaurant brand, bringing together healthful food and bold, satisfying flavors at scale. It operates through the following segments: CAVA and CAVA Foods. The CAVA segment includes the operations of all company-owned CAVA restaurants. The CAVA Foods segment includes the production of dips and spreads used in CAVA restaurants as well as sales from the consumer-packaged goods (CPG) business. The company was founded by Brett Schulman, Ike Grigoropoulus, Dimitri Moshovitis, and Theodore Xenohristos in 2010 and is headquartered in Washington, DC.

Cava Group Inc

CAVA Group Inc

CAVA is trending as the stock experiences notable price volatility, prompting discussions around potential bottom fishing and averaging down strategies among investors. Recent news of the COO's departure appears to be weighing on the stock, while some community members see a disconnect between the stock price and the company's fundamentals, citing solid growth and good earnings. Broader market sentiment around fast-casual restaurants and consumer spending is also influencing the conversation.

AKIRA LABS

AKIRA.X is trending alongside other tokens like WAGMI.X and SOL.X, with many users expressing bullish sentiment and referring to it as a potential "gem." The community seems to be focused on the potential for "meme season" profits and touting AKIRA.X as a better investment than others.

statis crypto Watchlist

Bitcoin

Ethereum

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SILK, MOR, AFBI, MGOL on Behalf of Shareholders

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SILK, MOR, AFBI, MGOL on Behalf of Shareholders SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SILK, MOR, AFBI, MGOL on Behalf of...

SHAREHOLDER ALERT: The M&A Class Action Firm Investigates Tender Offer Expiring August 2, 2024, of MorphoSys AG - MOR

SHAREHOLDER ALERT: The M&A Class Action Firm Investigates Tender Offer Expiring August 2, 2024, of MorphoSys AG - MOR SHAREHOLDER ALERT: The M&A Class Action Firm Investigates Tender Offer Expiring...

MorphoSys Announces Voluntary Delisting from the Nasdaq Global Market

MorphoSys AG (FSE: MOR; NASDAQ: MOR) today announced that it has formally notified the Nasdaq Stock Market of its intention to voluntarily delist its American Depositary Shares (ADSs) from the Nasdaq...

Kuehn Law Encourages DM, SHCR, MOR, and ALE Investors to Contact Law Firm

Kuehn Law Encourages DM, SHCR, MOR, and ALE Investors to Contact Law Firm Kuehn Law Encourages DM, SHCR, MOR, and ALE Investors to Contact Law Firm PR Newswire NEW YORK, July 8, 2024 NEW YORK, July...

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates BEST, MOR, HCP, SQSP on Behalf of Shareholders

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates BEST, MOR, HCP, SQSP on Behalf of Shareholders SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates BEST, MOR, HCP, SQSP on Behalf of...

MOR STOCK ALERT: Halper Sadeh LLC Is Investigating Whether the Sale of MorphoSys AG Is Fair to Shareholders

Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of MorphoSys AG (NASDAQ: MOR) to Novartis for 68.00 per share in cash is fair to MorphoSys shareholders. Halper Sadeh...

MorphoSys and Novartis Sign Delisting Agreement and Intend to Implement a Merger Squeeze-out of MorphoSys Minority Shareholders

MorphoSys AG (FSE: MOR; NASDAQ: MOR) today announced that the company has entered into a delisting agreement with Novartis BidCo AG and Novartis AG following the successful closing of the acquisition...

MorphoSys AG Reports First Quarter 2024 Financial Results

MorphoSys AG (FSE: MOR; NASDAQ: MOR) reports results for the first quarter of 2024. The proposed acquisition by Novartis is advancing steadily, and we continue to anticipate its closure in the first...

MorphoSys Says Novartis Deal Progressing Steadily Despite Safety Concerns Over Bone Marrow Cancer Drug, Pelabresib

MorphoSys faces safety concerns over pelabresib, a myelofibrosis treatment. Physicians report patients transitioning rapidly to acute myeloid leukemia. FDA alerted. Novartis acquisition proceeds...

Futures Rise, Yen Downgraded To Banana Republic Currency After Another Rollercoaster Session

Futures Rise, Yen Downgraded To Banana Republic Currency After Another Rollercoaster Session

 US equity futures swung between gains and losses and traded near session highs as US traders...

MorphoSys AG is a biotechnology companies focusing on fully human antibodies. With its unique technologies, MorphoSys is developing the next generation of antibodies, which can be used to treat diseases and for research and diagnostics purposes. Numerous partnerships have already been entered into with well-known companies from the pharmaceutical and biotechnology sectors, such as Boehringer Ingelheim, Daiichi Sankyo, Merck & Co, Novartis, Pfizer, and Roche.

Morphosys AG - ADR

0 to 25,000

25,000 to 50,000

50,000 to 75,000

75,000 to 100,000

How many jobs did the U.S. add in September? Vote below + drop your exact prediction in the comments. 
 
*Powered by Polymarket

Current Price	$18.63
Prev Close	$18.51
Open	$18.75
Dividend Yield	N/A
50-Day Moving Average	$18.41
Beta	1.03
Avg. Volume	31,989.64
PE Ratio	-5.47

52-Week High	$19.50
52-Week Low	$4.19
Market Capitalization	$2.86B
EPS (Annual)	N/A
Price to Book	-10.11
Revenue Per Employee	N/A
Enterprise Value/EBITDA	N/A

MOR
MorphoSys AG ADR

Feed

News

Sentiment

Fundamentals

Info

Latest MOR News

MOR MorphoSys AG ADR